

Regenerative Medicine Crossroad in Tokyo #9 on January 28, 2019 (the Event)

Organization	Name of Organization / 会社名
	QIMR Berghofer Medical Research Institute
	URL
	www.qimrberghofer.edu.au
	Brief Descriptions of Organization / 会社概要
	<p>QIMR Berghofer is one of Australia's most successful medical research institutes. The Institute was established 70 years ago by the Queensland Government and has a rich history of scientific discoveries and translational medical research. QIMR Berghofer is focused on improving health by developing new diagnostics, better treatments and prevention strategies, specifically in the areas of cancer, infectious diseases, mental health and complex disorders.</p> <p>Working in close collaboration with clinicians and other research institutes, QIMR Berghofer is home to more than 600 scientists, students and support staff. The Institute has an active program for the patenting and commercialisation of technologies, including those developed in conjunction with academic or commercial collaborators.</p> <p>QIMR Berghofer also has facilities for the GMP manufacture of cell-based and molecular therapies, namely Q-Gen Cell Therapeutics. Also co-located within the Institute is a commercial Phase I/II clinical trials facility, Q-Pharm Pty Ltd, allowing QIMR Berghofer scientists and external clients the extended and unique capability for taking research findings from the laboratory bench to the hospital bedside.</p>

Oral Presentation	Title of Presentation / 講演タイトル
	<i>Cellular Immunotherapies for cancers, autoimmune disease and infectious complications</i>
	Abstract / 要旨
	<p>Over the past 20 years, QIMR Berghofer scientists have developed a number of platform technologies for cellular immunotherapies to treat a diverse range of diseases. They are world-leaders in developing immunotherapies for the treatment of human cancers and infectious complications. These platform technologies have been used to conduct phase I and II clinical trials for brain cancer, head and neck cancer, viral infections in transplant patients and multiple sclerosis. These trials have included both autologous and allogeneic immunotherapies conducted in Australia, the USA and Hong Kong with well over 150 participants. In addition, QIMR Berghofer has ongoing pre-clinical development work focused upon next-generation technologies including novel chimeric antigen receptor technologies for cancer immunotherapy, immunotherapies for new and emerging infectious diseases and a regulatory T cell immunotherapy program for the treatment of graft-versus-host disease and other autoimmune disorders. Manufacturing of these cellular therapies occurs within QIMR-Berghofer at the dedicated Q-Gen Cell Therapeutics facility. This facility is licensed by the Australian regulator (TGA) for GMP manufacture of immune cellular therapies for clinical trials. Q-Gen has collaborated with academic, medical and commercial partners to manufacture cell therapy products for clinical trials in Australia, USA, Europe and Asia.</p>
	Objectives and/or Motives / 目的
	<p>QIMR Berghofer is looking for commercial and collaborative partnerships with biopharma and academic partners to develop novel T-cell and T-reg cell therapies. Our GMP accredited cell therapy manufacturing facility, Q-Gen Cell Therapeutics can offer partners cell therapy manufacturing for clinical trials. We can also assist partners to undertake clinical trials in Australia, including collaborating with CROs to access fast track approvals for early phase studies.</p>